** Shares of vaccine maker Novavax NVAX.O rise 28.9% to $7.67 premarket
** Co swings to Q1 profit from a year-ago loss, helped by reduced costs related to the development and sale of its COVID-19 vaccines
** Says discussions with the US FDA regarding its proposed study design for its COVID-19 vaccine are ongoing
** Reports Q1 net income came of $519 million, compared to a net loss of $148 million a year earlier
** Reports quarterly revenue of $667 million up from $94 million a year ago, and beating analysts' estimate of $343.85 million, as per data compiled by LSEG
** Last month, the U.S. health regulator asked Novavax to produce more data on its COVID-19 vaccine if it gets full approval
** Up to last close, NVAX down 26% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。